Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Note: See also these related newsletters: 13 Jan 2019 on DTR as part of the language of resistance, 7 Jun 2020 on using DTR to estimate
20 February 2020
No Comments
PK & PK-PD
FDA posts 4 RFPs! MIC breakpoints, PRO for ABPA, dosing in obesity/CRRT!
Dear All, Whew … still catching up after all the activities of World Antimicrobial Awareness Week (WAAW)! More to follow on some of that great content,
2 December 2021
No Comments
FDA workshop: Animal models to support antibacterial development (5 Mar 2020)
Dear All (moderately long note alert; be sure to note the new list of funding opportunities just below my signature), FDA have announced a public workshop
4 February 2020
No Comments
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Dear All (detailed and wonkish note alert … lots of thinking out loud … get some coffee and settle in!), I wrote previously (link) about
8 March 2020
No Comments
High-resolution (effectively 3-D) drug concentration measurements in tissues
Dear All: I’m really not trying to flood your inbox with email, but when ideas surface I do like to pass them on. As an
18 August 2017
No Comments
NIAID workshop: What is a robust PK-PD package?
Dear All: The ~150 of us who gathered in Washington yesterday and today for the NIAID’s PK-PD workshop enjoyed a very rich conversation. It’s really
15 June 2017
No Comments
Real-time continuous in vivo drug monitoring
Dear All: I recently became aware of a technology for real-time continuous in vivo monitoring of drug levels that I thought worth sharing with the
17 August 2017
No Comments
PK measures in space and time: Summary of high-resolution methods
Dear All: I recently sent around discussions of ways to measure/estimate drug concentrations both in living animals (aptamer-based probes, Kevin Plaxco’s group) and with sufficient spatial resolution
25 August 2017
No Comments
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
Dear All: FDA today hosted their eagerly awaited workshop on animal models in support of narrow-spectrum agents for A. baumannii (Abau) and P. aeruginosa (Pae). It was a really
1 March 2017
No Comments
FDA AMDAC – Developing Single-Pathogen agents for P. aeruginosa and A. baumannii
Dear All (and with apologies … long note alert!): Yesterday’s AMDAC was very productive. For reference, all the materials are here and a reasonably detailed set of
13 April 2017
No Comments